General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR website: www.iiar-anticancer.org

Selection of Recent Articles

Small Molecule GS-Nitroxide Ameliorates Ionizing Irradiation-Induced Delay in Bone Wound Healing in a Novel Murine Model. A. GORHALE, J.-C. RWIGEMA, M. EPPEL, J. GLOWACKI, W. HANK, P. WIPF, J. GOFF, T. DIXON, K. PATRENE, J. GREENBERGER (Pittsburgh, PA; Boston, MA, USA)


Effects of Voluntarily Ingested Buprenorphine on Plasma Corticosterone Levels, Body Weight, Water Intake, and Behaviour in Permanently Catheterised Rats. R. GOLDRUHL, J. HAU, K.S.P. ABELSON (Uppsala, Sweden; Copenhagen, Denmark)

Pharmacologic Ascorbic Acid Suppresses Syngeneic Tumor Growth and Metastases in Hormone-Refractory Prostate Cancer. H.B. POLLARD, M.A. LEVINE, O. EIDELMAN, M. POLLARD (Bethesda, MD; Notre Dame, IN, USA)


Modulation of Aged Murine T Lymphocytes In Vivo by DPV576-C, a Nanodiamond- and Nanoplatinum-coated Material. M. GHONEUM, A. GHONEUM, L. TOLENTINO, J. GIMZEWSKI (Los Angeles, CA, USA)


Effects of Fetal Exposure to 4-n-Octylphenol on Mammary Tumorigenesis in Rats. H. KAWAGUCHI, N. MIYOSHI, Y. MIYAMOTO, M. SOUDA, Y. UMEKITA, N. YASUDA, H. YOSHIDA (Kagoshima, Japan)

Comparative Study of Difference Between Long and Short Pulse on Treating Melanoma In Vivo. X. CHEN, R.J. SWANSON, K.H. SCHNEIDER, S. ZHENG (Zhejiang, China; Norfolk, VA, USA)

Tetrandrine Pre-Treatment has Protective Effects Against Isoproterenol-induced Myocardial Infarction in Rabbits. A. PINELLI, S. TRIVULZIO, S. BRENNA, G. ROSSONI (Milan, Italy)

Postinfectious and Chronic Fatigue Syndromes: Clinical Experience from a Tertiary-referral Centre in Norway. H. NAESS, E. SUNDA, K.-M. MYHR, H.I. YLAND (Bergen, Norway)

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research
1st km Kapandriotou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.
Tel: +30 22950 52945, Fax: +30 22950 53389
e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGEN-WERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (Düsseldorf, Germany)

Cancer-related Issues of CD147. U.H. WEIDLE, W. SCHEUER, D. EGGLE, S. KLOSTERMANN, H. STOCKINGER (Penzburg, Germany; Vienna, Austria)

Spontaneous In Vitro Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAML, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (Muenchen; Düsseldorf; Rostock, Germany)

Inhibition of c-Jun N-terminal Kinase (JNK) by SP600125 : A cDNA Microarray Analysis. P. CHAMPELOVIER, M. EL ATIFI-BOREL, J.P. ISSARTEL, J. BOUTONNAT, F. BERGER, D. SEIGNEURIN (Grenoble, France)

Transforming Acidic Coiled-coil-containing Protein 2 (TACC2) in Human Breast Cancer, Expression Pattern and Clinical/Prognostic Relevance. S. CHENG, A. DOUGLAS-JONES, X. YANG, R.E. MANSEL, W.G. JIANG (Cardiff, UK; Beijing, China)

Spontaneous In Vitro Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAML, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (Muenchen; Düsseldorf; Rostock, Germany)

Metalloproteome of the Prostate: Carcinoma Cell Line DU-145 in Comparison to Healthy Rat Tissue. J. BARTEL, E. CHARKIEWICZ, T. BARTZ, J. BARTEL, D. SCHMIDT, I. GRBAVAC, A. KYRIAKOPOULOS (Berlin, Germany)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J. AL-RUWAILI, S.E.T. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, P.A. TOWNSEND, C.L. AUKIM-HASTIE (Portsmouth; Southampton, UK; Riyadh, Saudi Arabia; Boston, MA, USA)

Identification of Serpin (α-1-antitrypsin) as Serum Growth Inhibitory Factor in Murine Ehrlich Carcinoma by Proteomics. F.V. DONENKO, R.K. ZIGANSHIN, N.Y. ANISIMOVA, K.E. VOYUSHIN, S.M. SITDIKOVA, B.S. AMANDZHOLOV, M.V. KISELEVSKII, T. EFFERTH (Moscow, Russia; Mainz, Germany)

DNA-Based Assay for EPB86 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (Pomona, CA, USA)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDEK. E. BLOMQVIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (Uppsala; Örebro; Gävle; Karlstad, Sweden; Mumbai, India)
The Size of Colon Polyps Revisited: Intra and Inter-observer Variations. C.A. RUBIO, J.G. JÓNASSON, G. NESI, J. MAZUR, E. ÓLAFSĐÓTTIR (Stockholm, Sweden; Reykjavik, Iceland; Florence, Italy; Warsaw, Poland) ................................................................. 2419

Number of Hysteroscopies and the Time Interval between Hysteroscopy and Surgery: Influence on Peritoneal Cytology in Patients with Endometrial Cancer. I. JUHASZ-BÖSS, T. FEHM, A. NAUTH, S. BECKER, R. ROTHMUND, K. GARDANIS, B. KRÄMER, D. WALLWIENER, E. SOLOMAYER (Tübingen; Homburg/Saar, Germany) ........................................................................................................................................... 2425

Frequent Expression of Thymidine Phosphorylase in Epstein-Barr Virus-associated Gastric Carcinoma of Diffuse Type. C. KORIYAMA, S. AKIBA, S. SHIMAOKA, T. ITOH, S.-I. AKIYAMA, Y. EIZURU (Kagoshima, Japan) .......................................................................................................................... 2431

HER-2/AKT Expression in Upper Urinary Tract Urothelial Carcinoma: Prognostic Implications. L. IZQUIERDO, D. TRUAN, L. MENGUAL, C. MALLOFRÉ, A. ALCARAZ (Barcelona; Santander, Spain) ........................................................................................................ 2439

Increased ERCC1 Protein Expression Is Associated with Suboptimal Debulking in Advanced Epithelial Ovarian Cancer. F. LIN, K. LIN, X. XIE, C. ZHOU (Zhejiang, PR China) ................................................................................................................................. 2447

Prognostic Impact of CD133 Expression in Gastric Carcinoma. S. ISHIGAMI, S. UENO, T. ARIGAMI, Y. UCHIKADO, T. SETOYAMA, H. ARIMA, Y. KITA, H. KURAHARA, H. OKUMURA, M. MATSUMOTO, Y. KIJIMA, S. NATSUGOE (Kagoshima, Japan) .......................................................................................................................... 2453

Lack of Prognostic Value of Topoisomerase II Alpha in Patients with Breast Cancer: Analysis with Tissue Microarray. S.-M. SHEEN-CHEN, C.-Y. HUANG, H. ZHANG, C.-C. HUANG, R.-P. TANG (Taoyuan, Taiwan, ROC; Xiamen, PR China) ........................................................................................................................................... 2459

Circulating HER2 DNA after Trastuzumab Treatment Predicts Survival and Response in Breast Cancer. B.S. SORESEN, L.S. MORTENSEN, J. ANDERSEN, E. NEXO (Aarhus, Denmark) ........................................................................................................................................... 2463

Medical History and Lifestyle Factors Contributing to Epstein-Barr Virus-Associated Gastric Carcinoma and Conventional Gastric Carcinoma in Korea. R.H. KIM, M.S. CHANG, H.J. KIM, K.S. SONG, Y.S. KIM, B.Y. CHOI, W.H. KIM (Seoul; Daejeon, South Korea) ........................................................................................................................................... 2469

Meeting Report: City of Temples Discusses Signaling Templates in Cancer Cells. Third International Symposium on Translational Cancer Research: Cell Signaling & Cancer Therapy Bhubaneswar, Orissa, India, December 18th through 21st, 2009. V. GANDHI, K. MEHTA, S. PATHAK, B. RAVINDRAN, S. MISHRA, B.B. AGGARWAL (Houston, TX, USA; Orissa, India) ........................................................................................................................................... 2477

Errata ................................................................................................................................. 2481

* Reviews (pages 1977, 2073, 2161)
A Phase IA, Open-label, Dose-escalating Study of PTK787/ZK 222584 Administered Orally on a Continuous Dosing Schedule in Patients with Advanced Cancer. J. DREVS, M. MEDINGER, K. MROSS, S. FUXIUS, J. HENNIG, M. BUECHERT, A. THOMAS, C. UNGER, B.-L. CHEN, D. LEBWOHL, D. LAURENT (Freiburg; Heidelberg; Berlin, Germany; Leicester, UK; East Hanover, NJ, USA)...................

Postoperative Concurrent Daily Low-dose Cisplatin-based Chemoradiation Improves the Prognosis of Patients with Pathologic T2b or N1 Cervical Cancer. A. MITSUHASHI, T. UNO, H. USUI, S. TATE, K. HIRASHIKI, K. KATO, H. KIYOHARA, S. KATO, H. ITO, M. SHOZU (Chiba, Japan)......................

An Indication for Correlation between the Serum ADA Level and Gastric Cancer Risk. G. RI, S. OHNO, M. FURUTANI, Y. FURUTANI, T. TSUKAHARA, N. HAGITA, H. HARUYAMA, S. NAKAMURA, T. YAMAMOTO, R. MATSUOKA (Tokyo; Saitama, Japan)....................................................................

A Case of Spontaneous Regression of Advanced Colon Cancer. H. SHIMIZU, M. KOCHI, T. KAIGA, Y. MIHARA, M. FUJII, T. TAKAYAMA (Tokyo, Japan)........................................................................

Pharmacokinetics of Irinotecan in Combination with Biweekly Cetuximab in Patients with Advanced Colorectal Cancer. M. CZEJKA, B. GRUENBERGER, A. KISS, A. FARKOUH, J. SCHUELLER (Vienna, Austria)......


Association of Hypoxia-inducible Factor 1-alpha Gene Polymorphisms and Colorectal Cancer Prognosis. J. SZKANDERA, G. KNECHTEL, M. STOTZ, G. HOFMANN, U. LANGSENLEHNER, P. KRIPPL, T. LANGSENLEHNER, D. DEHCHAMANI, H. SAMONIGG, W. RENNER, A. GERGER (Graz; Fuerstenfeld, Austria)........................................................................................................

Evaluation of Women with Breast Disease Using Body Image Drawing Analysis. M. ESKELINEN, P. OLLONEN (Kuopio, Finland)........................................................................................................


Clinical Studies


Phase I Study of Oral Vinorelbine and Capecitabine in Patients with Metastatic Breast Cancer. A. ANTON, A. LLUCH, A. CASADO, M. PROVENCIO, M. MUÑOZ, J. LAO, B. BERMEJO, A.B. PAULES, J. GAYO, M. MARTIN (Zaragoza; Valencia; Madrid; Barcelona, Spain) .................................................. 2255

Effects of α-Difluoromethylornithine on Markers of Proliferation, Invasion, and Apoptosis in Breast Cancer. E. IZBICKA, R.T. STREEPER, I-T. YEH, O. PRESSLEY, M. GRANT, J. V.R. ANDREWS, J. KUHN, J. O’SHAUGHNESSY (San Antonio; Dallas, TX, USA) ................................................................. 2263

Connexin43, E-Cadherin, β-Catenin and ZO-1 Expression, and Aberrant Methylation of the Connexin43 Gene in NSCLC. Y. JINN, N. INASE (Kanagawa; Tokyo, Japan) ................................................................. 2271

Aberrant Expression of Vimentin Correlates with Dedifferentiation and Poor Prognosis in Patients with Intrahepatic Cholangiocarcinoma. P.V. KORITA, T. WAKAY, Y. AJIOKA, M. INOUE, M. TAKAMURA, Y. SHIRAI, K. HATAKEYAMA (Niigata, Japan) ........................................................................ 2279

Surgical Excision for B3 Breast Lesions Diagnosed by Vacuum-assisted Core Biopsy. S. REEFY, H. OSMAN, C. CHAO, N. PERRY, K. MOKBEL (London; Tooting, UK) .......................................................... 2287

Cyfra 21-1 as a Tumor Marker for Follow-up of Patients with Squamous Cell Carcinoma of the Oropharynx. K. ALKOTYFAN, S. WIEGAND, H.-H. MÜLLER, J.P. WINDFUHR, J.A. WERNER, A.M. SESTERHENN (Marburg; Moenchengladbach, Germany) ........................................................................ 2291

The Impact of the Extent of Lymph-node Dissection on Biochemical Relapse after Radical Prostatectomy in Node-negative Patients. R. SCHIAVINA, A. BERTACCINI, A. FRANCESCHELLI, F. MANFERRARI, V. VAGNONI, M. BORGHESI, A.M. MORSELLI-LABATE, G. MARTORANA (Bologna, Italy) ................................................... 2297

Vincristine in High-grade Glioma. B. AYDIN, M. PATIL, N. BEKELE, J.E.A. WOLFF (Ankara, Turkey; Houston, TX, USA) ............... 2303


Short-term Outcome of Cervical Intraepithelial Neoplasia Grade 2: Considerations for Management Strategies and Reproducibility of Diagnosis. A.C. GUEDES, L.C. ZEFERINO, K.J. SYRJÄNEN, S.M.F. BRENN (São Paulo, Brazil; Turku, Finland) .................................................. 2319


Relationship between Preoperative Serum Markers CA 15-3 and CEA and Relapse of the Disease in Elderly (>65 years) Women with Breast Cancer. F. LUMACHI, S.M.M. BASSO, M. BONAMINI, B. MARZANO, E. MILAN, B.U. WACLAW, G.B. CHIARA (Padova; Pordenone, Italy) ........................................ 2331

Contents continued on the preceding page
AKT and p21WAF1/CIP1 as Potential Genistein Targets in BRCA1-mutant Human Breast Cancer Cell Lines. M. PRIVAT, C. AUBEL, S. ARNOULD, Y. COMMUNAL, M. FERRARA, Y.-J. BIGNON (Clermont-Ferrand, France) .......................................................... 2049

The Influence of Electroporation on Cytotoxicity of Anticancer Ruthenium(III) Complex KP1339 In Vitro and In Vivo. R. HUDEJ, I. TUREL, M. KANDUSER, J. SCANCAR, S. KRANIC, G. SERSA, D. MIKLAVCIC, M.A. JAKUPEC, B.K. KEPPLER, M. CEMAZAR (Ljubljana, Slovenia; Vienna, Austria) .................................................................................... 2055


* Review: An Overview of Nanotechnology-based Functional Proteomics for Cancer and Cell Cycle Progression. C. NICOLINI, E. PECHKOVÁ (Genoa, Rome, Italy) ....................................................................................................................... 2073

Long-term Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Pulsed Dendritic Cells. M. KRAEMER, S. HAUSER, I.G.H. SCHMIDT-WOLF (Bonn, Germany) ...................................................................................................................... 2081

Clioquinol Independently Targets NF-κB and Lysosome Pathways in Human Cancer Cells. H. YU, J.R. LOU, W.-Q. DING (Wuhan, PR China; Oklahoma City, OK, USA) ................................................................. 2087

Proteomic Analysis for Nuclear Proteins Related to Tumour Malignant Progression: A Comparative Proteomic Study Between Malignant Progressive Cells and Regressive Cells. Y. KURAMITSU, E. HAYASHI, F. OKADA, T. TANAKA, Z. ZHANG, Y. UEYAMA, K. NAKAMURA (Ube; Nagasaki, Japan) ................................................................. 2093

Antisense Inhibition of Amphiregulin Expression Reduces EGFR Phosphorylation in Transformed Human Breast Epithelial Cells. L. MA, E. HUET, M. SEROVA, Y. BERTHOIS, F. CALVO, S. MOURAH, S. MENASHI (Beijing, PR China; Créteil; Paris; Marseille, France) .......................................................................................................................... 2101


Analysis of Apoptotic Effects Induced by Photodynamic Therapy in a Human Biliary Cancer Cell Line. T. NONAKA, A. NANASHIMA, M. NONAKA, M. UEHARA, H. ISOMOTO, I. ASAHINA, T. NAGAYASU (Nagasaki, Japan) ........................................................................................................................................ 2113

Differential Ex Vivo Activity of Bortezomib in Newly Diagnosed Paediatric Acute Lymphoblastic and Myeloblastic Leukæmia. J. SZCZEPANEK, M. POGORZALA, B. KONATKOWSKA, E. JURASZewsKA, W. BADOWSKA, I. OLEJNIK, M. KUZMicz, E. STANCZAK, I. MALINOWSKA, J. STEFANIAK, G. SOBOL, T. SZCZEPANSKI, K. CZYZEWSKI, M. WYSOCKI, J. STYCZYNski (Bydgoszcz; Poznan; Cracow; Olszyn; Chorzow; Warsaw; Lublin; Katowice; Zabrze, Poland) ........................................................................................................ 2119


Phenylen Isothiocyanate Inhibits Migration and Invasion of Human Gastric Cancer AGS Cells through Suppressing MAPK and NF-κB Signal Pathways. M.-D. YANG, K.-C. LAI, T.-Y. LAI, S.-C. HSU, C.-L. KUO, C.-S. YU, M.-L. LIN, J.-S. YANG, H.-M. KUO, S.-H. WU, J.-G. CHUNG (Taichung; Yunlin; Changhua, Taiwan, ROC) ......................................................................................................................... 2135

Contents continued on the preceding page
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Location(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bortezomib Therapeutic Effect Is Associated with Expression and Mutation of FGFR3 in Human Lymphoma Cells.</td>
<td>W. ZHENG, M. GUAN, L. ZHU, Z. CAI, V. CHUNG, H. HUANG, Y. YEN</td>
<td>Zhejiang, PR China; Duarte, CA, USA</td>
<td>1921</td>
</tr>
<tr>
<td>Efficacy of Recombinant Adeno-Associated Viral Vectors Serotypes 1, 2, and 5 for the Transduction of Pancreatic and Colon Carcinoma Cells.</td>
<td>C. TESCHENDORF, B. EMONS, N. MUZYCZKA, U. GRAEVEN, W. SCHMIEGEL</td>
<td>Bochum, Germany; Gainesville, FL, USA</td>
<td>1931</td>
</tr>
<tr>
<td>Function and Regulatory Mechanisms of the Candidate Tumor Suppressor Receptor Protein Tyrosine Phosphatase Gamma (PTPRG) in Breast Cancer Cells.</td>
<td>S.T. SHU, Y. SUGIMOTO, S. LIU, H.-L. CHANG, W. YE, L.-S. WANG, Y.-W. HUANG, P. YAN, Y.C. LIN</td>
<td>Columbus, OH, USA</td>
<td>1937</td>
</tr>
<tr>
<td>VEGF Targeting in Mesotheliomas Using an Interleukin-6 Signal Inhibitor Based on Adenovirus Gene Delivery.</td>
<td>Y. ADACHI, N. YOSHIO-HOSHINO, C. AOKI, N. NISHIMOTO</td>
<td>Ibaraki-City; Suita City, Osaka, Japan</td>
<td>1947</td>
</tr>
<tr>
<td>In Vitro Interaction of High-LET Heavy-ion Irradiation and Chemotherapeutic Agents in Two Cell lines with Different Radiosensitivities and Different p53 Status.</td>
<td>T. TAKAHASHI, T. FUKAWA, R. HIRAYAMA, Y. YOSHIDA, A. MUSA, Y. FURUSAWA, K. ANDO, T. NAKANO</td>
<td>Gunma; Chiba, Japan</td>
<td>1961</td>
</tr>
<tr>
<td>KRAS and BRAF Mutation Analysis from Liquid-based Cytology Brushings of Colorectal Cancer in Comparison with Formalin-fixed, Paraffin-embedded Tissue.</td>
<td>A. SPATHIS, J. GEORGOULAKIS, P. FOUKAS, M. KEFALA, K. LEVENTAKOS, A. MACHAIRAS, I. PANAYITIDES, P. KARAKITOS</td>
<td>Athens, Greece</td>
<td>1969</td>
</tr>
<tr>
<td>Therapeutic Effects of Hybrid Liposomes on Gastric Carcinoma Involve Apoptosis.</td>
<td>H. ICHIHARA, Y. MATSUOKA, Y. MATSUMOTO, R. UEOKA</td>
<td>Kumamoto, Japan</td>
<td>2011</td>
</tr>
<tr>
<td>Protective Effects of the Immunopotentiator from Pantoea agglomerans 1 on Chemotherapeutic Agent-induced Macrophage Growth Inhibition.</td>
<td>T. HEBISHIMA, Y. MATSUMOTO, G. WATANABE, G.-I. SOMA, C. KOCHHI, K. TAYA, Y. HAYASHI, Y. HIROTA</td>
<td>Tokyo; Gifu; Tokushima; Kagawa, Japan</td>
<td>2033</td>
</tr>
<tr>
<td>Inhibition of Wnt Signaling Pathway Decreases Chemotherapy-resistant Side-population Colon Cancer Cells.</td>
<td>N. CHIKAZAWA, H. TANAKA, T. TASAKA, M. NAKAMURA, M. TANAKA, H. ONISHI, M. KATANO</td>
<td>Fukuoka, Japan</td>
<td>2041</td>
</tr>
</tbody>
</table>